We also tested expression of each protein against all other clinicopathological variables (age, gender, Dukes stage, post-operative chemotherapy, pre-operative radiotherapy, site of tumour, KRAS mutation status, BRAF mutation status, MSI and trial group, i.e. placebo/rofecoxib). This evidence concerns the gene KRAS and neoplasm.